Tuesday, May 22, 2018

RET inhibitor shows potential in RET-altered solid tumours

The potent and highly selective RET* inhibitor BLU-667 was well-tolerated and exhibited promising clinical activity among patients with advanced, RET-altered solid cancers that progressed despite multikinase inhibitor therapy, according to data presented at AACR 2018.

No comments:

Post a Comment

PCSK9 inhibitors show superior LDL-C lowering effects to ezetimibe

Proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitor is superior to ezetimibe in reducing low-density lipoprotein cholesterol (LDL-C),...